CV: ARRHYTHMIAS, bradycardia, chest pain, HF, hypotension, palpitations, peripheral edema, syncope, tachycardia.
Derm: dermatitis, erythema multiforme, flushing, photosensitivity, pruritus/urticaria, rash, STEVENS-JOHNSON SYNDROME (SJS), sweating.
EENT: blurred vision, disturbed equilibrium, epistaxis, tinnitus.
Endo: gynecomastia, hyperglycemia.
GI: ↑ liver enzymes, anorexia, constipation, diarrhea, dry mouth, dyspepsia, nausea, vomiting.
GU: dysuria, nocturia, polyuria, sexual dysfunction, urinary frequency.
Hemat: anemia, leukopenia, thrombocytopenia.
Metab: weight gain.
MS: joint stiffness, muscle cramps.
Neuro: abnormal dreams, anxiety, confusion, dizziness/lightheadedness, drowsiness, dysgeusia, extrapyramidal reactions, headache, jitteriness, nervousness, paresthesia, psychiatric disturbances, tremor, weakness.
Resp: cough, dyspnea.
Misc: gingival hyperplasia.
Calan, Calan SR, Verelan, Verelan PM
Therapeutic Classification: antianginals, antiarrhythmics (class IV), antihypertensives, vascular headache suppressants
Pharmacologic Classification: calcium channel blockers
Absorption: 90% absorbed after oral administration, but much is rapidly metabolized, resulting in bioavailability of 20–25%.
Distribution: Well distributed to tissues.
Protein Binding: 90%.
Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 isoenzyme. Primarily excreted in urine (4% as unchanged drug).
Half-life: 4.5–12 hr.
(cardiovascular effects)
†Single dose; effects from multiple doses may not be evident for 24–48 hr.
‡Antiarrhythmic effects; hemodynamic effects begin 3–5 min after injection and persist for 10–20 min.
